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Highlights: 
 Recurrent short sleep duration is associated with flatter slope in diurnal cortisol.  
 Chronic insomnia symptoms predict a steeper morning rise in cortisol.   
 
 
 
Abstract  
Although an association between both sleep duration and disturbance with salivary cortisol 
has been suggested, little is known about the long term effects of poor quality sleep on 
diurnal cortisol rhythm. The aim of this study was to examine the association of poor quality 
sleep, categorised as recurrent short sleep duration and chronic insomnia symptoms, with the 
diurnal release of cortisol. We examined this in 3,314 participants from an occupational 
cohort originally recruited in 1985-1989. Salivary cortisol was measured in 2007-2009 and 
six saliva samples were collected: 1) waking, 2) waking + 0.5h, 3) + 2.5h, 4) +8h, 5) +12h 
and 6) bedtime, for assessment of the cortisol awakening response and the diurnal slope in 
cortisol secretion. Participants with the first saliva sample collected within 15 min of waking 
and not on steroid medication were examined. Short sleep duration (≤5 hours) and insomnia 
symptoms (Jenkins scale, highest quartile) were measured in 1997-1999, 2003-2004 and 
2007-2009.  Recurrent short sleep was associated with a flatter diurnal cortisol pattern. A 
steeper morning rise in cortisol was observed among those reporting chronic insomnia 
symptoms at three time points and among those reporting short sleep twice, compared to 
those who never reported sleep problems. Participants reporting short sleep on three 
occasions had higher levels of cortisol later in the day, compared to those never reporting 
short sleep, indicated by a positive interaction with hours since waking (β=0.02 (95% CI: 
0.01, 0.03). We conclude that recurrent sleep problems are associated with adverse salivary 
cortisol patterns throughout the day.   
 
Keywords: sleep duration; insomnia symptoms; cortisol 
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1. Introduction 
Poor quality sleep is associated with a number of chronic conditions including type 2 
diabetes, coronary heart disease and hypertension (Cappuccio, 2007; Cappuccio et al., 2010; 
Chandola et al., 2010; Knutson et al., 2006; Larcher et al., 2015; Shan et al., 2015) and 
mortality (Ferrie, 2007; Rod et al., 2014). The hypothalamic-pituitary-adrenal (HPA) axis has 
been suggested as a potential mechanism for this association, since experimental evidence 
has found that sleep deprivation is associated with temporary changes in HPA-related stress 
markers, such as cortisol (Meerlo et al., 2008).  A recent narrative review evaluated evidence 
on sleep and cortisol (Garde et al., 2012) and concluded that there was a positive association 
between sleep duration and salivary cortisol on waking. However, many of the studies 
reviewed reported no significant association and sample sizes in most cases were modest. 
Only four studies were based on a sample of more than 200 participants (Kumari et al., 2009; 
Schlotz et al., 2004; Vreeburg et al., 2009; Wust et al., 2000). One of these found evidence of 
associations between both short sleep duration, sleep disturbance and a flatter diurnal cortisol 
secretion slope in a middle-aged occupational cohort (Kumari et al., 2009).  In this study 
short sleep duration (5h or less) was also associated with an increased cortisol awakening 
response  (Kumari et al., 2009. ). Based on laboratory studies, plausible mechanisms by 
which short sleep duration may alter diurnal cortisol include the diminution of the feedback 
mechanism of cortisolregulation  (Dahlgren et al., 2009) or minimising the secretion of 
corticotropin  (Steiger, 2002). As with sleep duration, evidence of an association between 
insomnia symptoms and cortisol is equivocal.  Some studies have found no association 
between measures of sleep quality or insomnia and salivary cortisol (Dahlgren et al., 2009; 
Eek et al., 2012; Hsiao et al., 2013). Although self-reported insomnia symptoms have been 
found to be associated with both lower cortisol waking values (Backhaus et al., 2004; Hansen 
et al., 2012)  and shallower slopes in cortisol (Hansen et al., 2012; Kumari et al., 2009). 
 
An association between sleep and cortisol was confirmed recently using actigraphy measured 
sleep duration and efficiency (Castro-Diehl et al., 2015). Castro-Diehl and colleagues (2015)  
found both shorter sleep and poor sleep quality to be associated with alterations in diurnal 
cortisol patterns. However, this study was unable to consider long-term variability in sleep 
duration or quality.  Much of the evidence has been cross-sectional, and therefore unable to 
determine the temporal nature of the relationship between sleep and cortisol.  Thus, a major 
drawback is the lack of knowledge about the consequences of sleep deprivation over longer 
periods of time as often occurs in real life.  These consequences might be negative; chronic 
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sleep problems might directly alter properties of neuroendocrine stress systems or disturb the 
reactivity of these systems (Meerlo et al., 2008; van Cauter et al., 2007). However, it is also 
possible that an individual might adapt to constant exposure to short sleep or insomnia 
symptoms, either as they age or through fluctuating sleep requirements.  To fully explore 
these changes, it is necessary to examine both sleep duration and disturbance over a number 
of years, which is only possible using longitudinal data.   
 
Despite evidence in younger age groups (Hatzinger et al., 2014; Kiel et al., 2015) , to the best 
of our knowledge there have been no longitudinal studies that have examined recurrent short 
sleep duration and chronic insomnia symptoms in relation to salivary cortisol in older adults. 
Longitudinal data are available in the Whitehall II study and accordingly, our objective in this 
paper is to address the gap in the literature and examine the association between poor quality 
sleep, characterised by recurrent short sleep duration and chronic insomnia symptoms, with 
the diurnal release of cortisol. Self-reported short sleep duration and insomnia symptoms 
were recorded three times over a 10-year period. Cortisol secretion was measured at the end 
of follow-up using saliva samples taken over a single day to capture the diurnal profile. We 
examined the morning rise in cortisol and the slope in diurnal cortisol separately.  The study 
has the advantage of being large enough to account for a number of covariates associated 
with both sleep and cortisol in the analyses.       
 
2. Method 
2.1 Participants 
The Whitehall II cohort was initially recruited in 1985-1988 from Civil Service departments 
based in London (phase 1), the final sample consisted of 10,308 participants aged 35-55 
(response rate 73%). Follow up screening examinations took place in 1991-1993 (phase 3), 
1997-1999 (phase 5), 2003-2004 (phase 7) and 2007-2009 (phase 9) with postal 
questionnaires being sent to participants in 1989 (phase 2), 1995 (phase 4), 2001 (phase 6) 
and 2006 (phase 8).  We used exposure data from three phases of this study (1997-1999, 
2003-2004 and 2007-2009) to measure chronic insomnia symptoms and duration.  Cortisol 
secretion from 2007-2009 was used.  The number of participants who were eligible for 
cortisol assessment in phase 9 was 6,044 and of those 5,106 (85%) returned samples. Further 
details of the Whitehall II Study can be found elsewhere. Ethical approval for the Whitehall II 
study was obtained from the University College London Medical School Committee on the 
Ethics of Human Research. 
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2.2 Sleep exposures  
Sleep duration and insomnia symptoms were self-reported at 1997-1999 (phase five), 2003-
2004 (phase 7) and 2007-2009 (phase 9). Sleep duration was measured by asking: “How 
many hours of sleep do you have on an average week night?”;  participants were offered five 
options  5h or less, 6h, 7h, 8h or 9h or more. Recurrent short sleep was defined as the 
number of times, out of three possible, that short (≤5 hours/night) sleep was reported; 
Chronic insomnia symptoms were measured using the Jenkins’ sleep problem scale 
(Jenkins et al., 1988). Participants were asked how many times during the last month they: (1) 
“ Have trouble falling asleep,” (2) “Have trouble staying asleep (i.e. waking  up far too 
early)” (3) “Wake up several times per night” and (4) “Wake up after usual amount of sleep 
feeling tired and worn out.” The following response categories were available: Not at all, 1-3 
days, 4-7 days, 8- 14 days, 15-21 days and 22-31 days. For the analysis this scale was 
summed and then grouped into quartiles. The first three quartiles were grouped together (low 
insomnia symptoms) and the fourth quartile was grouped separately (high insomnia 
symptoms). Chronic insomnia symptoms were defined as number of times out of three 
possible that a high level of insomnia symptoms were reported.  
 
2.3 Cortisol data collection and outcome 
The data collection procedure for the collection of salivary cortisol at phase 9 in Whitehall II 
has been reported previously (Singh-Manoux et al., 2014). Participants who agreed were 
asked to take six samples using salivettes over the course of a normal weekday. They were 
instructed to take these at the following times:  un-rested at waking (sample 1), waking  + 30 
min (sample 2), waking + 2.5 h (sample 3), waking +8 h (sample 4), waking + 12 h (sample 
5), and bedtime (sample 6). Participants were asked to record the time of sample collection in 
a logbook and were also required to provide information on their wake time and stressful 
events on the day of sampling. The mean (m), SD (sd) and range (r) for the six sampling 
times are as follows: sample 1 (m:07:00, sd:01:03, r:11:31 ), sample 2 (m:07:31, sd:01:03, 
r:11:31), sample 3 (m:09:34, sd:01:04, r:11:01), sample 4 (m:15:05, sd:01:06, r:12:01 ), 
sample 5 (m:19:05, sd:01:14, r:11:31), sample 6 (m:19:12, sd:08:16, r:15:00).  Sensitivity 
analysis was conducted which excluded samples which lay more than 2 SD from the mean 
time of collection. The salivettes and logbook were then returned via the mail in a prepaid 
envelope. Salivette devices were centrifuged at 3000 rpm for 5 min, resulting in a clear 
supernatant of low viscosity. Salivary cortisol levels were measured using a commercial 
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immunoassay with chemiluminescence detection (CLIA; IBL-Hamburg, Hamburg, 
Germany). The limit of detection was 0.44 nmol/liter; intra- and interassay coefficients of 
variance were less than 8%. Any sample greater than 50 nmol/liter was repeated. 
 
Cortisol values for each of the six samples were excluded if they lay more than 3 SDs from 
the mean cortisol concentration for their sample. However, despite this, the distribution was 
skewed, so cortisol data were transformed by natural logarithm. The variable “hours since 
waking” was based on the respondents’ recorded waking time and time of sampling in the log 
book. Stress on the day of cortisol sampling was measured using a question from the logbook 
that asked whether the participant had experienced a stressful event and if so how stressful 
this was. These responses were coded into binary categories: no/moderately and very/most 
stressed ever felt. 
 
2.4 Covariates 
Several covariates, measured at phase nine (2007-2009), were also included: Age, sex, 
current or last known employment grade, smoking status and Body Mass Index (BMI). A 
binary variable was also created to capture high alcohol intake, (≥14 units/week for women 
and ≥22 units/week for men).  The Short form-36 health survey (SF-36) is a 36 item 
questionnaire which measures health related well-being (Ware et al., 1994). We used both the 
physical and mental functioning component scores considered to be conceptually distinct 
measures of physical (SF-36: PCS) and mental well-being (SF-36: MCS). Self-reported 
steroid medication (local and systemic), sleeping tablets and anti-depressant use in the last 14 
days was extracted using British National Formulary codes (BNF).   
 
2.5 Analysis  
As the cortisol samples are clustered within individuals, the data were analysed using 
multilevel models. Two separate growth curve models were considered. The first analysed 
the ln(cortisol) data from the first two samples (at waking and after 30 min) to examine the 
morning rise in cortisol. The second analysed the first (waking), third (2h after waking), 
fourth (8h after waking), fifth (12h after waking), and bedtime samples to examine the 
diurnal slope in cortisol. In each of these models, ln(cortisol) was regressed on hours since 
waking and the sleep exposure variables (recurrent short sleep and chronic insomnia 
symptoms), with dummy variables for the cortisol samples. Interaction terms between the 
sleep variables and hours since waking were included in the models to test whether the 
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cortisol profiles in the morning or later in the day differed between the sleep groups as time 
increased.  
 
3. Results 
The initial sample was composed of 5,106 respondents who returned the saliva samples. Of 
those 4,862 respondents had six usable cortisol measures and had completed the logbook, and 
4,763 had no missing sample times. Of these, 4,498 were not taking corticosteroid 
medications, and 4,172 respondents took their first sample within 15 min of waking without 
doing any activity first.  Restricting analyses to participants who collected the second sample 
within 15–45 min of waking, the third sample within 1–4 h since waking, the fourth sample 
within 5–10 h since waking, and the fifth sample within 10–14 h since waking restricted the 
sample to 3,990 respondents. After eliminating outliers (N=173) and taking into account 
missing covariates, the analytical sample included 3,125 respondents. A supplementary table 
comparing key covariates for those included and those excluded from the sample is available 
in the appendix (Table A.1).   
 
Table 1 reports the characteristics of the participants included in the study at phase 9 by 
chronic insomnia symptoms and recurrent short sleep duration. Overall 87.1% of the sample 
(N=2,722) reported no occurrences of short sleep at any of the phases and 2.2% of the sample 
(N=69) reported short sleep at every phase, these participants reported stable patterns of short 
sleep duration.  Altogether 7.8% (N=243) of the sample reported only one occurrence of short 
sleep; of these 2.6% (N=81) reported this at phase one, 2.2% (N=70) at phase two and 2.9% 
(N=92) at the third phase. Around 2.9% (N=91) of the sample reported two occurrences of 
short sleep duration, of these N=28 were from phases 5 and 7, N=21 were from phases 5 and 
nine and N=42 were from phases 7 and 9).  Mean cortisol at each sample time is consistent 
across occurrences of chronic insomnia symptoms. Participants that report recurrent short 
sleep are more likely to be from the lowest employment grades, have higher BMI scores and 
be smokers.  Table 2 shows results for the regression of ln(cortisol) on waking, at 2.5h, 8h, 
12h and at bedtime on recurrent short sleep. Results adjusted for waking time show an 
average linear slope for ln(cortisol) of -0.14 in those with no occurrences of short sleep; this 
reflects a decline in cortisol across the day. The squared term for hours since waking is 
positive (0.003) indicating that the magnitude of this decline reduces gradually throughout 
the day. This is seen in Figure 1. 
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Short sleep on three occasions, at phases 5, 7 and 9, is associated with a lower level of 
cortisol on waking, compared with never reporting short sleep. The significant interaction 
terms between the number of occasions of short sleep and hours since waking indicate that, as 
the day progresses, those with short sleep on any occasion, compared to no short sleep, have 
a shallower decline in ln(cortisol)  throughout the day. Compared with the decline in 
ln(cortisol) of -0.14 per hour in those with no occurrences of short sleep, those who reported 
three occurrences of short sleep have a decline of -0.12 (β =-0.14+0.02) per hour. Therefore, 
in addition to starting with lower levels of cortisol, they ‘catch-up’ across the day and end up 
with higher levels.  In Figure 1, a flatter cortisol slope is visible for those who reported short 
sleep on any occasion, especially those who reported it on three occasions. These effects 
remain in Model 2, after controlling for age, sex, employment grade, smoking, SF-36 (PCS & 
MCS), BMI and chronic insomnia symptoms.  Sensitivity analyses following removal of 
sample time outliers made no difference to the results.  
 
We repeated these analyses using chronic insomnia symptoms. In contrast to recurrent short 
sleep, ln(cortisol) was not significantly associated with chronic insomnia symptoms and the 
decline in cortisol through the day was unaffected. 
 
Table 3 shows the adjusted and unadjusted models of ln(cortisol) on waking and after 30min, 
regressed on exposure to recurrent short sleep. There is a significant interaction between short 
sleep on two occasions and hours since waking. Those who reported short sleep on two or 
more occasions have low levels of cortisol when they wake, compared to those who report no 
short sleep.  As displayed in Figure 2, the morning rise was steepest for those who reported 
short sleep on two occasions.  These results were robust in Model 2 to additional adjustment 
for other covariates. Table 3 also shows the morning rise in cortisol associated with chronic 
insomnia symptoms. Those who reported high insomnia symptoms on three occasions have 
lower levels of cortisol when they wake compared to those who never reported high insomnia 
symptoms. There is also a significant interaction between hours since waking and high 
insomnia symptoms on three occasions. As shown in Figure 3 this results in a steeper rise in 
morning cortisol among those reporting high insomnia symptoms on three occasions 
compared to those who never report insomnia symptoms.  Potential differences by sex in the 
results were examined by including a three way interaction (sleep exposure x hours since 
waking x sex). These were not found to be significant for any of the results.  P values for 
these interactions are reported in footnotes to Table 2 and Table 3.  
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4. Discussion 
To our knowledge, this is the first study to describe the association between sleep problems, 
measured repeatedly over time, and cortisol patterns throughout the day.  Different 
associations between the measures of sleep were observed for the decline in cortisol across 
the day (slope) and the morning rise in cortisol on waking.  Our novel findings indicate that 
recurrent short sleep but not chronic insomnia symptoms is associated with flatter slopes for 
cortisol across the day. A steeper rise in cortisol on waking was observed for those who 
reported three occurrences of high insomnia symptoms and recurrent short sleep was also 
associated with a steeper rise in cortisol. However this pattern was inconsistent as it reached 
statistical significance only for those who reported short sleep on two, but not three 
occasions. The associations observed between recurrent short sleep or high insomnia 
symptoms and cortisol were each independent of the other sleep measure. Furthermore, they 
were independent of a range of covariates including time of waking on the day of saliva 
sample collection.  Whilst previous findings in this area are unclear is because of small 
sample size and a lack of repeat measures, our findings in a large scale study with repeat data 
help clarify the literature (Garde et al., 2012).  
 
4. 1 Short sleep 
Our finding that recurrent short sleep is associated with the diurnal slope in cortisol accords 
with previously described cross-sectional associations for sleep duration and cortisol (Castro-
Diehl et al., 2015; Garde et al., 2012; Kumari et al., 2009). The fact that recurrent short sleep 
was associated with a flatter diurnal slope in cortisol, independent of chronic insomnia 
symptoms, suggests that it is the shorter sleep duration itself which predicts a flatter cortisol 
slope across the day. Waking time has also been found to be associated with salivary cortisol 
(Federenko et al., 2004; Stalder et al., 2009)  in some previous studies, although due to the 
smaller samples studied, it was not always possible to separate the effects of waking time 
from sleep duration (Federenko et al., 2004). In this study, the associations between sleep 
duration and cortisol remained consistent when the time at waking was taken into account.  
While it is possible that those who reported short sleep might be thought to be collecting both 
their first and last samples early in the morning, this is not the explanation for our 
observations as in our sample, only 28% of those who reported sleeping for less than 5hours 
at all three time points collected their first sample earlier than 7am and their last sample later 
than midnight. 
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4.2 Insomnia symptoms 
Although a cross sectional association has also been found between insomnia symptoms and 
the diurnal slope in cortisol (Castro-Diehl et al., 2015; Hansen et al., 2012; Kumari et al., 
2009), we did not find a similar relationship in this study.  This could suggest that the effect 
of sleep quality on the cortisol diurnal slope is only apparent in the case of immediate or short 
term insomnia symptoms. A steeper morning rise in cortisol was observed for those who 
reported high insomnia symptoms on three occasions and for those who reported short sleep 
on two occasions. Cross-sectional research which reported an association between sleep and 
cortisol after waking, found a decrease for those reporting sleep disturbance or insomnia 
(Backhaus et al., 2004; Hansen et al., 2012) and an increase after restricted or short sleep 
(Vreeburg et al., 2009; Wust et al., 2000).  However, differences in the measurement of both 
the exposure and the outcome make it difficult to draw clear comparisons with previous 
research. Our findings may suggest a common underlying mechanism of disturbed sleep, 
which is responsible for alterations in morning cortisol levels. However, the association 
between a morning rise in cortisol and reporting two occurrences of short sleep was 
independent of chronic insomnia symptoms. Therefore, a steeper rise in cortisol may be 
associated with reporting fluctuating sleep patterns over a long time period, either in terms of 
duration or disturbance.   
 
There are several mechanisms through which restricted or poor-quality sleep can influence 
cortisol secretion. Waye and colleagues (Waye et al., 2003) suggested that lower levels of 
morning cortisol may be due to increased HPA-axis activation during the night, which would 
be applicable for those with poor quality sleep in this study. Sleep debt has itself been 
hypothesised as a stressor (McEwen, 2006) and experimental evidence in this area has 
concluded that restricting sleep has an impact on the metabolic and endocrine functions of 
animals and young healthy volunteers (McEwen, 2006; Meerlo et al., 2008; Spiegel et al., 
1999). It has been proposed that continued exposure to restricted sleep will have long term 
consequences for the reactivity of these systems and will increase the risk of long-term health 
problems (McEwen, 2006; Spiegel et al., 1999). McEwen and colleagues argued that these 
long term consequences of sleep on the systems on the body represent allostatic load, where 
the accumulated wear and tear on the body systems of too much stress has resulted in poor 
adaptation (McEwen, 2006). Similar arguments have been presented by others and although 
the effects of sleep deprivation on glucocorticoid levels may be small, if recurrent, these 
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might represent a significant change to the adaption possibilities of a system (Meerlo et al., 
2008). 
 
While the findings presented here are independent of a wide range of co-variates, we cannot 
discount residual confounding. Many factors about the relationship between stress and sleep 
remain unknown; for example, we were not able to identify the reasons why participants 
reported either short sleep duration or insomnia symptoms. We did not control for depression 
in our analysis because of the overlap with poor sleep, but we adjusted our results for SF-36 
scores, which would take into account general physical and mental health functioning in our 
sample. We also conducted sensitivity analyses excluding those who were currently taking 
anti-depressants and the results remained unchanged.  Observing this association across three 
time points supports the notion that short sleep duration may precede changes in cortisol 
secretion in early old age, although further research in this area is needed firmly to establish 
the direction of this association. 
 
A key strength of this study was that cortisol levels were assessed repeatedly across a day by 
a large cohort of participants who appeared to understand and follow the protocol 
appropriately. However, these measures were only taken over the course of a single day, 
which may make it hard to gauge average cortisol production or 24-hr exposure. Another 
strength of this study is that both of the exposures assessed (recurrent short sleep and chronic 
insomnia symptoms) were measured at three time-points. Although a limitation is that these 
exposure measures were self-reported, assessments in the primary healthcare setting also rely 
on self-reports from patients. Observational studies are beginning to include objectives 
measures of sleep duration; however these were not available in 1995 when these data were 
first collected in the Whitehall II study.  Additionally, these objective measures are less 
sensitive to insomnia symptoms. We are not able to take sleep conditions, e.g. sleep apnoea, 
into account since these are not measured in our study; however, we did take BMI into 
account in our analyses. This should partially account for the potential confounding of this 
association since those diagnosed with sleep apnoea are more likely to be obese. Finally the 
data used in this study are from an occupational cohort of middle-aged, white-collar civil 
servants and therefore the generalizability of these findings would need to be confirmed in 
further studies.  
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We conclude that long term sleep problems are associated with salivary cortisol and that the 
patterns of these associations vary for sleep duration and disturbance. 
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Figure 1:  Diurnal cortisol slope by recurrent short sleep (mean predicted value of ln 
(cortisol) by  
Hours since waking, estimated from model 1, Table 2). 
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Figure 2:  Morning rise in cortisol by recurrent short sleep (mean predicted value of ln 
(cortisol) by  
Hours since waking, estimated from model 1, Table 3). 
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Figure 3:  Morning rise in cortisol by chronic insomnia symptoms (mean predicted value of 
ln (cortisol) by  
Hours since waking, estimated from model 1, Table 3). 
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Table 1: Characteristics of participants at Whitehall II phase 9 (2007-2009) 
N= 3,064  Chronic insomnia symptoms  Recurrent short sleep duration  
 
Mean (SD) or (%) 
ALL 
 
(N= 
3064) 
No 
occurrence
s 
(N= 1998) 
One 
occurren
ce 
(N=524) 
Two 
occurrence
s 
(N=310) 
Three 
occurrence
s 
(N=232) 
P value No 
occurrenc
es 
 (N=2672) 
One 
occurren
ce 
(N=234) 
Two 
occurren
ces 
(N=90) 
Three 
occurre
nces 
(N=68) 
 
P value 
Mean Cortisol at:            
Waking (nmol/l) 14.8 
(7.3) 
15.1 (7.4) 14.5 
(6.8) 
14.6 (6.9) 14.0 (7.6) 0.05 c 15.0 (7.3) 14.2 
(7.1) 
13.2 
(7.8) 
12.4 
(7.6) 
<0.001c 
Waking+30min 
(nmol/l) 
21.3 
(10.6) 
21.3 (10.7) 21.4 
(10.2) 
21.3 (10.7) 21.5 (10.1) 0.91 c 21.4 
(10.5) 
20.9 
(10.8) 
22.2 
(11.1) 
20.1 
(10.1) 
0.60 c 
Waking+2.5h 
(nmol/l) 
9.7 (6.0) 9.6 (5.9) 9.8 (5.7) 9.6 (6.1) 9.9 (6.4) 0.89 c 9.6 (5.9) 10.0 
(5.9) 
10.3 
(6.6) 
10.6 
(7.3) 
0.38 c 
Waking+8h (nmol/l) 6.0 (3.6) 5.8 (3.3) 5.8 (3.5) 5.8 (3.5) 6.0 (4.0) 0.84 c 5.9 (3.5) 6.2 (4.0) 5.8 (3.8) 5.9 
(3.6) 
0.77 c 
Waking+12 (nmol/l) 3.4 (2.8) 3.4 (2.8) 3.4 (2.8) 3.2 (2.5) 3.3 (2.2) 0.71 c 3.3 (2.7) 3.8 (3.2) 3.5 (2.2) 2.9 
(2.0) 
0.03 c 
Bedtime (nmol/l) 2.5 (2.4) 2.6 (2.4) 2.6 (2.5) 2.5 (2.6) 2.3 (1.8) 0.59 c 2.5 (2.2) 3.1 (3.6) 2.9 (3.2) 3.4 
(3.4) 
0.004 c 
Waking time  06:58 07:00 06:55 06:51 06:57 0.07 d 07:01 06:45 06:41 06:27 <0.001 
d 
High stress  2.45 1.70 2.9 3.2 6.9 <0.001 
e 
2.2 3.0 3.3 8.8 0.005 e 
Sex (% men) 74.5  78.5  71.6  65.5 58.6 0.001 e 76.2  63.7  65.6  55.9 <0.001e 
Age (yr) 65.9 65.9 66.2 65.7 66.0 0.78d 65.9 66.3 65.5 66.2 0.69d 
Lowest employment 
grade (%) 
7.2 7.1 5.9 8.1 9.9 0.02 e 6.1  12.8  12.2 22.1 0.001e 
SF-36 MCS 54.3 
(7.7) 
56.0 (6.0) 53.0 
(8.1) 
51.0 (9.3) 47.3 (10.7) <0.001 
d 
54.7 (7.3) 52.3 
(9.3) 
51.5 
(10.3) 
52.0 
(9.3) 
<0.001 
d 
SF-36 PCS 49.2 50.6 (7.1) 47.8 46.2 (9.8) 45.2 (10.7) <0.001d 49.6 (8.1) 47.7 46.1 45.6 <0.001 
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(8.3) (9.2) (9.7) (9.8) (10.0) d 
Current Smoker (%) 6.0  6.3 5.7 5.2 5.2 0.78 e 5.9 7.3  4.4  8.8 0.56 e 
High alcohol intake 14.8 14.4 16.0 14.5 16.0 0.77 e 15.1 11.5 16.7 13.2 0.47 e 
BMI (Kg/m2) 26.5 
(4.2) 
26.3 (4.1) 26.8 
(4.2) 
27.2 (4.5) 27.1 (4.8) <0.001 
d 
26.4 (4.2) 27.4 
(4.4) 
27.1 
(4.7) 
28.0 
(5.0) 
<0.001 
d 
Sleeping tablets 1.2 0.5 1.7 2.9 4.3 <0.001 
e 
1.0 2.6 4.4 1.5 0.008 e 
Anti-depressants 5.9 3.6 7.3 11.3 15.5 <0.001 
e 
5.3 12.8 5.6 5.9 <0.001 
e 
Steroid medication 3.4 3.1 2.9 4.2 6.0 0.09 e 3.4 2.1 3.3 7.4 0.22 e 
a Number of  times high level of insomnia symptoms reported; b Number of  times short sleep reported. c Kruskal-Wallis, d Anova e Chi squared 
f Fisher's exact. BMI; body mass index; SF-36 (MCS), Short Form Health Survey mental well-being component scores; SF-36 (PCS), Short 
Form Health Survey physical component scores. 
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Table 2: Ln(cortisol) on waking and waking plus 2.5, 8, and 12h and bed time (diurnal slope) on recurrent short sleep and chronic 
insomnia symptoms 
N= 3,064 Recurrent short sleep duration Chronic Insomnia Symptoms 
 Model 1 Model 2 Model 1 Model 2 
 β (SE) P value β (SE) P value β (SE) P value β (SE) P value 
Hours since waking -0.141  (0.048) 0.004 -0.139  (0.048) 0.004 -0.149  (0.048) 0.002 -0.151 
(0.048) 
0.002 
Hours since waking squared  0.005  (0.002) 0.003 0.005 (0.002) 0.003 0.005  (0.002) 0.001 0.005  
(0.002) 
0.001 
 Recurrent short sleep (frequency)     
No occurrences of short sleep REF REF     
One occurrence -0.029  (0.035) 0.411 -0.017  (0.036) 0.635     
Two occurrences -0.108  (0.056) 0.052 -0.094  (0.056) 0.088     
Three occurrences   -0.190  (0.063) 0.003 -0.163  (0.064) 0.010 
 
    
 Interaction: hrs since waking* short sleep     
No occurrences of short sleep REF REF     
One occurrence*Hours since waking a 0.009  (0.004) 0.015 0.009  (0.004) 0.015     
Two occurrences*Hours since waking b 0.014  (0.006) 0.014 0.014  (0.006) 0.014     
Three occurrences*Hours since waking c 0.020  (0.006) 0.002 0.020  (0.006) 0.002     
     Chronic insomnia symptoms (frequency) 
No occurrences of  insomnia symptoms d     REF  REF  
One occurrence     0.003  (0.026) 0.912 0.004  
(0.026) 
0.884 
Two occurrences     -0.015  (0.032) 0.628 -0.020 
(0.033) 
0.548 
Three occurrences       -0.052  (0.036) 0.154 -0.060 0.123 
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(0.039) 
     Interaction:  hrs since waking* insomnia symptoms 
No occurrences of  insomnia symptoms      REF  REF  
One occurrence*Hours  since waking e     -0.001  (0.003) 0.802 -0.001 
(0.003) 
0.801 
Two occurrences*Hours  since waking f     -0.003  (0.003) 0.322 -0.003 
(0.003) 
0.320 
Three occurrences* Hours  since waking 
g 
    0.002  (0.004) 0.553 0.002 (0.004) 0.552 
 
a p= 0.58 for one occurrence of short sleep x hours since waking x sex;  b   p= 0.61 for two occurrences  of short sleep x hours since waking x sex c   p 
value=0.86   three  occurrences  of short sleep x hours since waking x sex   d Insomnia symptoms: defined as number of times, across three time points, 
participant was in fourth quartile of reported insomnia symptoms  ep= 0.71 for one occurrence of insomnia symptoms x hours since waking x sex; f  p= 
0.96 for two occurrences  of insomnia symptoms x hours since waking x sex  g  p value=0.44   three  occurrences  of insomnia symptoms x hours since 
waking x sex   Model 1: Recurrent short sleep (frequency) adjusted for cortisol sample number (dummy variables for whether the cortisol came from 
first/third/fourth/fifth/sixth sample – estimates of these, compared to the first sample are, -0.17, -0.20, -0.66 and -0.98 respectively) +waking time, stress of 
day of sampling. Model 2: Model 1 + age, sex, employment grade, smoking, alcohol intake, SF-36 Short Form Health Survey (physical and mental 
component scores) BMI (Body Mass Index), steroids, anti-depressants, sleeping drugs , + other sleep exposure. 
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Table 3: Ln(cortisol) on waking and after 30 min (morning rise) on recurrent short sleep and chronic insomnia symptoms 
N= 3,064 Recurrent short sleep duration Chronic Insomnia Symptoms 
 Model 1 Model 2 Model 1 Model 2 
 β (SE) P value β (SE) P value β (SE) P value β (SE) P value 
Hours since waking 0.78 (0.18) <0.001 0.75 (0.18) <0.001 0.74 (0.18) <0.001 0.73 (0.18) <0.001 
Hours since waking squared  -0.77 (0.21) <0.001 
 
-0.77 (0.21) <0.001 
 
-0.76 (0.21) <0.001 -0.76 (0.21) <0.001 
 Recurrent short sleep (frequency):     
No occurrences of short sleep         
One occurrence -0.05 (0.04) 0.266 -0.03 (0.05) 0.45     
Two occurrences -0.20 (0.07) 0.003 -0.19 (0.07) 0.007     
Three occurrences   -0.26 (0.08) 0.001 -0.22 (0.08) 0.005 
 
    
 Interaction: hrs since waking* short sleep     
No occurrences of short sleep         
One occurrence*Hours since waking a -0.00 (0.11) 0.980 -0.03 (0.11) 0.99     
Two occurrences*Hours since waking b 0.45 (0.17) 0.008 0.46 (0.17) 0.008     
Three occurrences*Hours since waking c 0.35 (0.20) 0.071 0.33 (0.20) 0.08     
     Chronic insomnia symptoms (frequency) 
No occurrences of insomnia symptoms d     REF  REF  
One occurrence     -0.02 (0.03) 0.485 -0.01 (0.03) 0.668 
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Two occurrences     -0.03 (0.04) 0.417 -0.01 (0.04) 0.798 
Three occurrences       -0.13 (0.04) 0.004 -0.10 (0.05) 0.046 
 
     Interaction: hrs since waking* insomnia 
symptoms 
No occurrences of insomnia symptoms      REF  REF  
One occurrence*Hours  since waking e     0.10 (0.08) 0.191 0.10 (0.08) 0.194 
Two occurrences*Hours  since waking f     0.02 (0.10) 0.826 0.02 (0.10) 0.833 
Three occurrences * Hours  since waking g     0.30 (0.11) 0.007 0.30 (0.11) 0.006 
 a p= 0.50 for one occurrence of short sleep x hours since waking x sex; b p= 0.09  for two occurrences  of short sleep x hours since waking x sex 
c p value=0.25   three  occurrences  of short sleep x hours since waking x sex   d Insomnia symptoms: defined as number of times, across three 
time points, participant was in fourth quartile of reported insomnia symptoms ep= 0.64 for one occurrence of insomnia symptoms x hours since 
waking x sex  fp= 0.69  for two occurrences  of insomnia symptoms x hours since waking x sex g p value=0.66   three  occurrences  of insomnia 
symptoms x hours since waking x sex; Model 1: adjusted for cortisol sample number (dummy variables for whether the cortisol came from 
first/second sample – estimates of these, compared to the first sample are, 0.14) +waking time, stress of day of sample. Model 2: Model 1 + age, 
sex, employment grade, smoking, SF-36 Short Form Health Survey (physical and mental component scores) BMI (Body Mass Index), steroids, 
anti-depressants, sleeping drugs + other sleep exposure 
 
